Company Filing History:
1 out of 378 
1 out of 721 
Years Active: 2014-2016
Title: Christof Wegscheid-Gerlach: Innovator in Pharmaceutical Chemistry
Introduction
Christof Wegscheid-Gerlach is a notable inventor based in Marburg, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target specific kinases involved in various diseases. With a total of 2 patents, his work has implications for the treatment of inflammation and cancer.
Latest Patents
Wegscheid-Gerlach's latest patents include innovative compounds that serve as inhibitors for critical kinases. The first patent, titled "Substituted Aminoquinoxalines as Tyrosine Threonine Kinase Inhibitors," focuses on substituted aminoquinoxaline compounds that can be used in pharmaceutical compositions for treating diseases. The second patent, "Substituted Imidazoquinoxalines," relates to compounds that inhibit Mps-1 Kinase or TTK, showcasing their potential in combating inflammation and cancer.
Career Highlights
Throughout his career, Christof Wegscheid-Gerlach has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Bayer Pharma and Bayer Intellectual Property GmbH. His experience in these organizations has allowed him to contribute to significant advancements in drug development.
Collaborations
Wegscheid-Gerlach has collaborated with esteemed colleagues, including Benjamin Bader and Ulf Bömer. These partnerships have fostered a collaborative environment that enhances innovation and research in pharmaceutical chemistry.
Conclusion
Christof Wegscheid-Gerlach stands out as an influential inventor in the realm of pharmaceutical chemistry. His patents and collaborations reflect his commitment to advancing medical science and improving treatment options for various diseases.